Dow Jumps Over 600 Points; Constellation Energy Posts Upbeat Earnings
U.S. stocks rallied Monday, led by tech and consumer discretionary shares. Constellation Energy beat Q3 estimates; oil fell while gold rose.
Stocks · News reference
Zura Bio Phase 2 Trial of Tibulizumab in Hidradenitis Suppurativa Fails to Meet Primary Endpoint
Zura Bio announced that its Phase 2 TibuSHIELD clinical trial for tibulizumab in patients with hidradenitis suppurativa did not meet its primary endpoint.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Zura Bio Says Phase 2 TibuSHIELD Study Of Tibulizumab In Hidradenitis Suppurativa Missed Primary And Key Secondary Endpoints
8-K filing — Zura Bio Ltd (ZURA)
Filed: 2026-11-09 AccNo: 0001104659-26-124149 Size: 236 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio has announced the issuance of equity-based inducement grants to new employees in accordance with Nasdaq listing requirements.
Zura Bio Files for Potential $700 Million Securities Offering
Zura Bio Limited filed an SEC document indicating a potential shelf offering of up to $700 million in securities.
Zura Bio Reports Inducement Grants to New Employees
Zura Bio Limited granted stock options to five new employees as an inducement for their employment.